Respiratory Drugs

Published by: Global Industry Analysts

Published: Jul. 1, 2006 - 318 Pages

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II. EXECUTIVE SUMMARY

1. Market Overview

Respiratory Diseases - Common and Serious

Rhinoviruses - Root Cause of Major Respiratory Diseases

Leading Asthmatic Drugs and their Patent Expiries

Antihistamine or Allergic Rhinitis Market

Leading Anti-Allergy Drugs and Patent Expiry Years

Current and Future Analysis

Regional Perspective

Product Segment Perspective

2. Common Respiratory Diseases - Overview

Influenza

Asthma

Factors Promoting Asthma

Treatment

Respiratory Distress Syndrome (RDS)

Symptoms

Complications Related to RDS

Analysis of RDS

Alternative Methods for the Treatment of RDS

Preventive Measures

Chronic Obstructive Pulmonary Disease

Characteristics and Symptoms of COPD

Risks Associated with COPD

Bronchitis

Respiratory Syncytial Virus (RSV)

3. Treatment of Respiratory Diseases - An Overview

Respiratory Therapy with Information Technology

Antiviral Drugs for Controlling Influenza and RSV Infections

Pulmonary Drug Delivery

Why are Lungs Considered a Good Alternative?

COPD - Taking a Toll on Human Lives

Upper Respiratory Tract Infections (URIs)

Respiratory Failure Management

CPAP: Non-Invasive Respiration

Face Masks: Carriers of Oxygen Therapy

Endotracheal Intubation and Ventilatory Support

Endotracheal Intubation Turns Perilous

Ventilator Strategy

Methods of Ventilation

Weaning from the Ventilator

Respiratory Support: A Broader Perspective

Humidification

Posture

Physiotherapy

Pharmacological Adjuncts

Sedation

New Drugs, Treatments Ease Life of Patients with Respiratory Problems

Progesterone

Partial Liquid Ventilation

Heliox

High-level PREP

Respiratory Failure

Types of Respiratory Failure

Factors Leading to Respiratory Failure

Blockage of air passage

Drug abuse or alcohol addiction

Obesity

Muscle weakness

Lung disorders and diseases

Abnormalities in Chest Walls

Cellular Disorders

Treatment for Respiratory Failure

Role of Health Care Teams

Long-Term Consequences of Respiratory Failures

Preventive Measures

Measures to Prevent the Recurrence of Respiratory Diseases

Telithromycin: Treatment for Respiratory Disorders

Consequences of Telithromycin

4. Recent Industry Activity

Arcadia Resources, Inc Acquires Remedy Therapeutics, L.L.C

Sirna Forms Alliance with GlaxoSmithKline

Pharmaxis Ltd and Nigaard Pharma Enters into Distribution Agreement

Teva Regains Leadership Position through Ivax Acquisition

AstraZeneca Submits Symbicort for US FDA Approval

Ranbaxy Laboratories Receives FDA Approval

Innovata Inks Development Agreement for Duohaler

Novartis Obtains License from Arrow Therapeutics for A60444 Molecule Inhibitor

Arakis Ltd and Vectura Group plc Initiate Phase IIb Clinical Trial of NVA237

Schering-Plough Receives FDA Approval for Asmanex

Isis Pharmaceuticals Develops ISIS 369645

Inyx Acquires Celltech Manufacturing Services from UCB

Ashton Pharmaceuticals Partners with Innovata and Merck

King Pharmaceuticals Collaborates with Inyx

Inyx Pharma Ltd. Bags a Contract from Generics

Alnylam Pharmaceuticals Initiates Phase I Trials on ALN-RSV01

MAP and Elan Extend their Agreement for Developing Advanced Version of Asthma Drug

Accentia Enters into Licensing Agreement with Collegium

Novartis Inks Agreement with Arakis and Vectura

Pfizer and Rigel Sign Collaborative Agreement

NicOx Enters into Developing and Licensing Agreement with Topigen

Merck to Strike a Licensing Deal with Innovata for Developing Respiratory Medicines

Lannett Receives Approval from FDA for the Distribution of Terbutaline Sulfate Tablets

GlaxoSmithKline Licenses Inhaled Respiratory Therapy from Theravance

Novartis’ Sandoz Completes Acquisition of Hexal AG

Sandoz Acquires Eon Labs

SkyePharma, PLC Enters into License Agreement with GlaxoSmithKline

Kos Pharmaceuticals Signs Agreement with Aventis Pharmaceuticals

US FDA Approves New Antibiotic, Ketek

Zambon Terminates Single-Agent Inhaler Project

Boehringer Ingelheim Pharmaceuticals Obtains FDA Approval for Atrovent HFA

Ranbaxy Receives FDA Approval for Loratadine and Pseudoephedrine Sulfate Tablets

Lincoln Pharmaceuticals Limited Introduces Gatilink, an Antibiotic

GlaxoSmithKline Forms Alliance with Theravance

Etiologics Acquires Bayer’s Pre-clinical Respiratory Research Group

IVAX Pharmaceutical Signs Pan-European Agreement with 3M

GlaxoSmithKline Inks Agreement with Theravance

Cadila Pharmaceuticals Ltd Launches Montelast for Asthma

Alpharma Unveils Generic Loratadine Syrup

Dr. Reddy’s Laboratories Launches Brancho-Vaxom

5. Focus on Select Players

Accentia Biopharmaceuticals, Inc. (US)

Aerogen, Inc. (US)

Aerovance, Inc (US)

airPharma (US)

AstraZeneca (UK)

Aventis Pharma Limited (India)

Bespak (UK)

Boehringer Ingelheim Pharmaceuticals, Inc (Germany)

Cadila Pharmaceuticals (India)

Dr. Reddy's Laboratories (India)

EvoGenix (Australia)

GlaxoSmithKline (US)

GlaxoSmithKline Pharmaceuticals Ltd. (India)

Inyx, Inc. (US)

The Merck Generics Group (Germany)

Novartis AG (Switzerland)

Pfizer, Inc. (US)

Ranbaxy Laboratories Limited (India)

Respironics, Inc (US)

Sandoz International GmbH (Germany)

Schering-Plough Corp (US)

6. Global Market Perspective

Table 1: Recent Past, Current and Future Analysis for Respiratory Drugs by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 2: World 10-Year Perspective for Respiratory Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)

Table 3: World Recent Past, Current and Future Analysis for Asthma Drugs by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 4: World 10-Year Perspective for Asthma Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)

Table 5: World Recent Past, Current and Future Analysis for Allergic Rhinitis Drugs by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 6: World 10-Year Perspective for Allergic Rhinitis Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)

Table 7: World Recent Past, Current and Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Drugs by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 8: World 10-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)

III. MARKET

1. The United States

A.Market Analysis

Current & Future Analysis

Market Scenario

Asthma

COPD

Leading Respiratory Drug Brands

Strategic Corporate Developments

Focus on Select Players

B.Market Analytics

Table 9: US Recent Past, Current and Future Analysis for Respiratory Drugs by Product Segment - Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 10: US 10-Year Perspective for Respiratory Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)

Market Analysis

Table 11: Canadian Recent Past, Current and Future Analysis for Respiratory Drugs by Product Segment - Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 12: Canadian 10-Year Perspective for Respiratory Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)

Market Analysis

Table 13: Japanese Recent Past, Current and Future Analysis for Respiratory Drugs by Product Segment - Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 14: Japanese 10-Year Perspective for Respiratory Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)

A.Market Analysis

Current & Future Analysis

Strategic Corporate Developments

Focus on Select Players

B.Market Analytics

Table 15: European Recent Past, Current and Future Analysis for Respiratory Drugs by Product Segment - Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 16: European 10-Year Perspective for Respiratory Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)

A.Market Analysis

Current & Future Analysis

Strategic Corporate Developments

Focus on Select Players

B.Market Analytics

Table 17: Rest of World Recent Past, Current and Future Analysis for Respiratory Drugs by Product Segment - Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 18: Rest of World 10-Year Perspective for Respiratory Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)

IV. COMPETITION

1. 3M Company (USA)

Table 19: First Quarter Sales Analysis: 2005-2006 (In US$ million)

Table 20: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ million)

Table 21: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 22: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)

Table 23: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)

Table 24: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

2. Accentia Biopharmaceuticals (USA)

Table 25: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)

Table 26: Half Yearly Sales Analysis by Business Segment: 2005-2006 (H1) (In US$ million)

Table 27: Half Yearly Sales Analysis by Quarter: 2005- 2006 (H1) (In US$ million)

Table 28: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 29: Annual Sales Analysis by Business Segment: 2004-2005 (In US$ million)

Table 30: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

3. Activaero GmbH (Germany)

4. Actavis (Iceland)

5. Acusphere, Inc. (USA)

Table 31: First Quarter Sales Analysis: 2005-2006 (In US$ thousands)

Table 32: Annual Sales Analysis: 2004-2005 (In US$ thousands)

6. Aerovance, Inc. (USA)

7. Airpharma LLC (USA)

8. Alkermes, Inc. (USA)

Table 33: Annual Sales Analysis: 2004-2006 (In US$ million)

9. Alnylam Pharmaceuticals, Inc. (USA)

Table 34: First Quarter Sales Analysis: 2005-2006 (In US$ million)

Table 35: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 36: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)

10. Altana AG (Germany)

Table 37: First Quarter Sales Analysis: 2005-2006 (In € million)

Table 38: Annual Sales Analysis: 2004-2005 (In € million)

Table 39: Annual Sales Analysis by Segment: 2004-2005 (In € million)

Altana Pharma Pvt., Ltd. (India)

11. Argenta Discovery Ltd. (UK)

12. Arrow Therapeutics (UK)

13. Ashton Pharmaceuticals Limited (UK)

14. Astrazeneca PLC (UK)

Table 40: First Quarter Sales Analysis: 2005-2006 (In US$ million)

Table 41: First Quarter Sales Analysis by Geographic Region: 2005-2006 (In US$ million)

Table 42: Annual Sales Analysis: 2003-2005 (In US$ million)

Table 43: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)

15. AtheroGenics, Inc. (USA)

16. Aurobindo Pharma Ltd. (India)

Table 44: Annual Sales Analysis: 2004-2005 (In INR million)

17. Bespak PLC (UK)

Table 45: Annual Sales Analysis: 2004-2005 (In £ million)

Table 46: Annual Sales Analysis by Segment: 2004-2005 (In £ million)

Table 47: Annual Sales Analysis by Geographic Region: 2004-2005 (In £ million)

18. Boehringer Ingelheim GmbH (Germany)

Boehringer Ingelheim Pharmaceuticals, Inc. (Germany)

Boehringer Ingelheim Ltd. (Germany)

Nippon Boehringer Ingelheim Co., Ltd. (Japan)

19. Breath Limited (USA)

20. Cadila Pharmaceuticals Ltd. (India)

21. Cardinal Health, Inc. (USA)

Table 48: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, March) (In US$ billion)

Table 49: Nine Months Sales Analysis by Segment: 2005- 2006 (Nine Months Ended, March) (In US$ billion)

Table 50: Annual Sales Analysis: 2004-2005 (In US$ billion)

Table 51: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion)

Table 52: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion)

Table 53: Annual Sales Analysis by Quarter: 2004-2005 (In US$ billion)

22. Chrysalis Technologies (USA)

23. Cipla Limited (India)

24. Clement Clarke International Ltd. (UK)

25. Clininvent Research Pvt., Ltd. (India)

26. Collegium Pharmaceutical, Inc. (USA)

27. Cytopia Ltd. (Australia)

Table 54: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ thousand)

28. Direct-Haler A/S (Denmark)

29. Elan Pharmaceuticals (USA)

30. Epigenesis Pharmaceuticals (USA)

31. Evogenix Ltd. (Australia)

32. GlaxoSmithKline PLC (UK)

Table 55: Annual Sales Analysis: 2004-2005 (In £ million)

Table 56: Annual Sales Analysis by Segment: 2004-2005 (In £ million)

Glaxosmithkline Pharmaceuticals Limited (India)

33. Healthline Aerosol Medicine (USA)

34. Innovata PLC (UK)

Table 57: Annual Sales Analysis: 2004-2005 (In £ million)

Table 58: Annual Sales Analysis by Geographic Region: 2004-2005 (In £ million)

35. Inyx, Inc. (USA)

Table 59: First Quarter Sales Analysis: 2005-2006 (In US$ million)

Table 60: Annual Sales Analysis: 2004-2005 (In US$ million)

36. Isis Pharmaceuticals, Inc. (USA)

Table 61: First Quarter Sales Analysis: 2005-2006 (In US$ million)

Table 62: First Quarter Sales Analysis by Business Segment: 2005-2006 (In US$ million)

Table 63: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 64: Quarterly Sales Analysis: 2004-2005 (In US$ million)

Table 65: Annual Sales Analysis by Business Segment: 2004-2005 (In US$ million)

37. King Pharmaceuticals, Inc. (USA)

Table 66: First Quarter Sales Analysis: 2005-2006 (In US$ million)

Table 67: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ million)

Table 68: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 69: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)

38. Kos Pharmaceuticals, Inc. (USA)

Table 70: First Quarter Sales Analysis: 2005-2006 (In US$ million)

Table 71: Annual Sales Analysis: 2004-2005 (In US$ million)

39. Lannett Company, Inc. (USA)

Table 72: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, March) (In US$ million)

Table 73: Annual Sales Analysis: 2004-2005 (In US$ million)

40. Lincoln Pharmaceuticals Ltd. (India)

41. MAP Pharmaceuticals, Inc. (USA)

42. Markos Mefar SpA (Italy)

43. Merck KGAA (Germany)

Table 74: Annual Sales Analysis: 2003-2005 (In € million)

Table 75: Annual Sales Analysis by Segment: 2004-2005 (In € million)

Merck Generics Group (Germany)

44. Nektar Therapeutics (USA)

Table 76: Annual Sales Analysis: 2004-2005 (In US$ million)

45. Nic Ox SA (France)

46. Nigaard Pharma AS (Norway)

47. Novartis AG (Switzerland)

Table 77: First Quarter Sales Analysis: 2005-2006 (In US$ million)

Table 78: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ million)

Table 79: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 80: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)

Table 81: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

Sandoz Deutschland GmbH (Germany)

48. OM Pharma (Switzerland)

49. Oriel Therapeutics, Inc. (USA)

50. Pall Corporation (USA)

Table 82: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, April) (In US$ million)

Table 83: Nine Months Sales Analysis by Business Segment: 2005-2006 (Nine Months Ended, April) (In US$ million)

Table 84: Nine Months Sales Analysis by Geographic Region: 2005-2006 (Nine Months Ended, April) (In US$ million)

Table 85: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 86: Annual Sales Analysis by Business Segment: 2004-2005 (In US$ million)

Table 87: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

51. PDL Biopharma, Inc. (USA)

Table 88: First Quarter Sales Analysis: 2005-2006 (In US$ million)

Table 89: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 90: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)

52. Pfizer, Inc. (USA)

53. Pharmaxis Ltd. (Australia)

54. Profile Therapeutics (UK)

55. Ranbaxy Laboratories Ltd. (India)

56. Respirics, Inc. (USA)

57. Respironics, Inc. (USA)

Table 91: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, March) (In US$ million)

Table 92: Nine Months Sales Analysis by Quarter: 2005- 2006 (Nine Months Ended, March) (In US$ million)

Table 93: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 94: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)

Table 95: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)

Table 96: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

58. Rigel Pharmaceuticals, Inc. (USA)

Table 97: First Quarter Sales Analysis: 2005-2006 (In US$ million)

Table 98: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 99: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)

59. Roche Holding AG (Switzerland)

60. Sanofi-Aventis (France)

Table 100: First Quarter Sales Analysis: 2005-2006 (In € million)

Table 101: Annual Sales Analysis: 2004-2005 (In € million)

Table 102: Annual Sales Analysis by Segment: 2004-2005 (In € million)

Table 103: Annual Sales Analysis by Geographic Region: 2004-2005 (In € million)

Aventis Pharma Ltd. (India)

61. Schering-Plough Corporation (USA)

Table 104: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 105: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)

Table 106: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

Table 107: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)

62. Sirna Therapeutics, Inc. (USA)

Table 108: First Quarter Sales Analysis: 2005-2006 (In US$ million)

Table 109: First Quarter Sales Analysis by Business Segment: 2005-2006 (In US$ million)

Table 110: Annual Sales Analysis: 2004-2005 (In US$ million)

63. Sosei Co., Ltd. (Japan)

Table 111: Annual Sales Analysis: 2005-2006 (In ¥ million)

Table 112: Annual Sales Analysis: 2004-2005 (In ¥ million)

64. Teva Pharmaceutical Industries Ltd. (Israel)

Teva Pharmaceuticals USA (USA)

65. Theravance, Inc. (USA)

Table 113: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 114: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)

66. Topigen Pharmaceuticals, Inc. (Canada)

67. UCB S.A. (Belgium)

Table 115: Annual Sales Analysis: 2004-2005 (In € million)

Table 116: Annual Sales Analysis by Business Segment: 2004-2005 (In € million)

68. Vectura Group PLC (UK)

Table 117: Annual Sales Analysis: 2004-2005 (In £ million)

Table 118: Annual Sales Analysis by Geographic Region: 2004-2005 (In £ million)

69. Zambon SpA (Italy)

Abstract

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location. Adobe Acrobat Reader 7.0 is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Titles available via "online download" are not affected by this and are still delivered to your personal library immediately.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.